Giotrif gets EU approval – update
This article was originally published in Scrip
Boehringer Ingelheim's targeted anticancer Giotrif (afatinib) has received EU approval for use in lung cancer. The company said it would launch Giotrif in EU countries as soon as possible, with the first due in the "coming few weeks".
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.